Lenard A. Adler, MD

Lenard AdlerDr. Adler is a Professor of Psychiatry and Child and Adolescent Psychiatry.  His current focus is on Attention-deficit/hyperactivity disorder (ADHD).  ADHD is a neuropsychiatric disorder that affects 6% to 9% of children, with clinically significant symptoms persisting into adulthood in 60% of cases. Epidemiologic data indicate that the prevalence of ADHD in adults is approximately 4% worldwide.  In the United States, about 8 million adults have ADHD, making it one of the most common psychiatric disorders.  Since 1995, the Adult ADHD Program, headed by Lenard A. Adler, M.D., has served as the basis for numerous diagnostic, neuropsychological and treatment studies, including stimulant, non-stimulant and novel agents, of adult ADHD.  Dr. Adler is also the co-inventor of several ADHD diagnostic and symptom assessment instruments, which have been used in multiple federally funded and industry-sponsored trials.

The Adult ADHD Program

The Adult ADHD Program is currently conducting several studies of ADHD in adults. The aim of one study is to address the lack of data comparing lisdexamfetamine dimesylate (LDX), the most recent FDA-approved psychostimulant for the treatment of ADHD, to short-acting amphetamine compounds by evaluating the pharmacokinetic profile of clinical response to subacute treatment with LDX versus the clinical response of subacute treatment with mixed amphetamine salts immediate release in adults with ADHD. The aim of a second study is to validate modifications made to the existing NYU/MGH Adult ADHD diagnostic and symptom assessment scales, which were revised to be consistent with the new diagnostic classification for adult ADHD proposed in the upcoming 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V). The aim of a third study is to improve the understanding of the longitudinal impact of ADHD by examining treatment patterns and outcomes, burden of illness, and costs associated with the disorder and its treatment.

Adult ADHD studies planned for the near future include examining deficits in executive functioning using the Cambridge Neuropsychological Test Automated Battery (CANTAB) and validating a 5-week manualized coaching program designed to augment pharmacotherapy for adult ADHD by targeting improvements in time management, organization and planning. Long-term research goals are to improve the recognition and treatment of ADHD in adults, develop psychosocial interventions, and to better understand the neuropsychological and functional impairments, deficits in executive functioning, and costs of the disorder.

Email: Lenard.Adler@nyumc.org

Representative Publications

  1. Adler, L.A., & Chua, H.C. (2002). Management of ADHD in Adults. Journal of Clinical Psychiatry, 63 Suppl 12, 29-35.
  2. Michelson, D., Adler, L., Spencer, T., Reimherr, F.W., West, S.A., Allen, A.J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biological Psychiatry, 53(2), 112-120.
  3. Adler, L.A., & Cohen, J. (2004). Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatric Clinics of North America, 27(2), 187-201.
  4. Adler, L.A., Spencer, T., Faraone, S.V., Reimherr, F.W., Kelsey, D., Michelson, D., & Biederman, J. (2005). Training raters to assess adult ADHD: reliability of ratings. Journal of Attention Disorders, 8(3), 121-126.
  5. Kessler, R.C., Adler, L.A., Barkley, R., Biederman, J., Conners, C.K., Faraone, S.V., Greenhill, L.L., Jaeger, S., Secnik, K., Spencer, T., Ustün, T.B., & Zaslavsky, A.M. (2005). Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biological Psychiatry, 57(11), 1442-1451.
  6. Kessler, R.C., Adler, L., Ames, M., Demler, O., Faraone, S., Hiripi, E., Howes, M.J., Jin, R., Secnik, K., Spencer, T., Ustün, T.B., & Walters, E.E. (2005). The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychological Medicine, 35(2), 245-56.
  7. Kessler, R.C., Adler, L., Barkley, R., Biederman, J., Conners, C.K., Demler, O., Faraone, S.V., Greenhill, L.L., Howes, M.J., Secnik, K., Spencer, T., Ustün, T.B., Walters, E.E., & Zaslavsky, A.M. (2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163(4), 716-723.
  8. Adler, L.A., Sutton, V.K., Moore, R.J., Dietrich, A.P., Reimherr, F.W., Sangal, R.B., Saylor, K.E., Secnik, K., Kelsey, D.K., & Allen, A.J. (2006). Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. Journal of Clinical Psychopharmacology, 26(6), 648-652.
  9. Adler, L.A. (2008). Familial transmission of ADHD and psychoactive substance use disorders. American Journal of Psychiatry, 165(1), 11-12.
  10. Adler, L.A., Spencer, T., Brown, T.E., Holdnack, J., Saylor, K., Schuh, K., Trzepacz, P.T., Williams, D.W., & Kelsey, D. (2009). Once-daily atomoxetine for adult ADHD: a six-month, double-blind trial. Journal of Clinical Psychopharmacology, 29(1), 44-50.
  11. Adler, L.A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009). Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depression and Anxiety, 26(3), 212-221.
  12. Adler, L.A., Weisler, R.H., Goodman, D.W., Hamdani, M., & Niebler, G.E. (2009). Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 70(12), 1652-1661.
  13. Winhusen, T.M., Somoza, E.C., Brigham, G.S., Liu, D.S., Green, C.A., Covey, L.S., Croghan, I.T., Adler, L.A., Weiss, R.D., Leimberger, J.D., Lewis, D.F., & Dorer, E.M. (2010). Impact of attention-deficit/hyperactivity disorder (ADHD) treatment on smoking cessation intervention in ADHD smokers: a randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry, 71(12):1680-8.
  14. Kessler, R.C., Green, J.G., Adler, L.A., Barkley, R.A., Chatterji, S., Faraone, S.V., Finkelman, M., Greenhill, L.L., Gruber, M.J., Jewell, M., Russo, L.J., Sampson, N.A., & Van Brunt, D.L. (2010). The structure and diagnosis of adult ADHD: An analysis of expanded symptom criteria from the adult ADHD Clinical Diagnostic Scale (ACDS). Archives of General Psychiatry, 67(11):1168-78.
  15. Adler L.A., Shaw D.M., Spencer T.J., Newcorn J.H., Sitt D.J., Morrill M., Davidow J.V., Glatt S.J., Faraone S.V. (2011) Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults. Compr Psychiatry, Epub: Feb 7.